Cox proportional hazard model for all-cause mortality.

<p>Variables in the model are as follows: age, gender, diabetes, hypertension, and the use of statin, aspirin, clopidogrel, beta blocker, CCB, ACEi, and ARB.</p><p>Abbreviations: ACEi, angiogensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.</p><p>Cox proportional hazard model for all-cause mortality.</p

Baseline characteristics of total study population.

<p>Data are mean±SD, median (IQR; Q1–Q3) or number (%).</p><p>*Chronic kidney disease was defined as estimated glomerular filtration rate (GFR) <60 mL/min/1.73m².</p><p>^†Calculations of the laboratory tests and coronary artery calcium score were performed for those with available data of each component.</p><p>^‡A composite of all-cause mortality and late coronary revascularization (>90 days after CCTA), including percutaneous coronary intervention and coronary artery bypass graft operation.</p><p>Abbreviations: COPD, chronic obstructive pulmonary disease; ACEi, angiogensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; GFR, glomerular filtration rate; CACS, coronary artery calcium score; CCTA, coronary computed tomography angiography.</p><p>Baseline characteristics of total study population.</p

Multivariable Cox proportional hazard model for the composite endpoint^*.

<p>* Composite endpoint: a composite of all-cause mortality and late coronary revascularization.</p><p>Abbreviations: ACEi, angiogensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.</p><p>Multivariable Cox proportional hazard model for the composite endpoint^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129584#t003fn001" target="_blank">*</a>}.</p

Association between post-CCTA aspirin therapy and the composite endpoint in subgroups.

<p>Risk-adjusted effects of aspirin therapy on the composite of mortality and late coronary revascularization (>90 days after CCTA) were analyzed in subgroups divided by age of 65 years, gender, presence of diabetes mellitus, presence of hypertension, and the results of CACS, LDL-C, hsCRP and GFR.</p

Selection of study population.

<p>Selection of study population.</p

Risk-adjusted survival curves of aspirin users versus non-users.

<p><b>A,</b> All-cause mortality-free survival by aspirin therapy in patients with non-obstructive coronary artery disease (1–49% stenosis). <b>B,</b> Composite endpoint (all-cause mortality or late coronary revascularization)-free survival by aspirin therapy. Survival analyses were performed using age, gender, comorbidities and concurrent medications as covariates.</p

Association between post-CCTA aspirin therapy and all-cause mortality in subgroups.

<p>Risk-adjusted effects of aspirin therapy on all-cause mortality were analyzed in subgroups divided by age of 65 years, gender, presence of diabetes mellitus, presence of hypertension, and the results of CACS, LDL-C, hsCRP and GFR.</p